Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.

Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.

After more than 40 years of use, Praziquantel (PZQ) still remains the drug of choice for the treatment of intestinal and urogenital schistosomiasis. Its anti-parasitic activity resides primarily in the (R)-enantiomer. Hitherto neither the molecular target nor the pharmacokinetic-pharmacodynamic rela...

Full description

Bibliographic Details
Main Authors:	Nada Abla, Jennifer Keiser, Mireille Vargas, Natalie Reimers, Helmut Haas, Thomas Spangenberg
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-09-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	http://europepmc.org/articles/PMC5626502?pdf=render

Similar Items

Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
by: Pierre H. H. Schneeberger, et al.
Published: (2018-03-01)

Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni
by: Naglaa Mohamed El-Lakkany, et al.
Published: (2011-11-01)

In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
by: Jana Kovač, et al.
Published: (2017-08-01)

Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel
by: Eglal I. Amer, et al.
Published: (2022-03-01)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of <i>Schistosoma mansoni</i> Infection
by: Omary Mashiku Minzi, et al.
Published: (2021-04-01)

Altered Response of Strain of Schistosoma mansoni to Oxamniquine and Praziquantel
by: Patrícia Ivana Pires Bonesso-Sabadini, et al.
Published: (2002-04-01)

Activity of praziquantel on in vitro transformed Schistosoma mansoni sporocysts
by: ACA Mattos, et al.
Published: (2006-10-01)

Praziquantel Treatment of Schistosoma mansoni Infected Mice Renders Them Less Susceptible to Reinfection
by: Justin Komguep Nono, et al.
Published: (2021-12-01)

Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
by: Jean T Coulibaly, et al.
Published: (2012-01-01)

Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial.
by: Beatrice Barda, et al.
Published: (2016-09-01)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni.
by: Gordana Panic, et al.
Published: (2015-01-01)

Praziquantel activates a native cation current in Schistosoma mansoni
by: Evgeny G. Chulkov, et al.
Published: (2023-11-01)

The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype.
by: António Pinto-Almeida, et al.
Published: (2015-01-01)

Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections.
by: Regina Coeli, et al.
Published: (2013-01-01)

Pathological and immunological evaluation of different regimens of praziquantel treatment in a mouse model of Schistosoma mansoni infection.
by: Ulrich Membe Femoe, et al.
Published: (2022-04-01)

Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial
by: Ferrari M.L.A., et al.
Published: (2003-01-01)

Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.
by: Sandra D Melman, et al.
Published: (2009-08-01)

Synergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult Worms.
by: Giulliana T Almeida, et al.
Published: (2015-01-01)

Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial.
by: Jennifer Keiser, et al.
Published: (2014-07-01)

(Ca2+-Mg2+)ATPase in Schistosoma mansoni: evidence for heterogeneity and resistance to praziquantel
by: VMN Cunha, et al.
Published: (1998-01-01)

Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection.
by: Joseph Bertin Kadji Fassi, et al.
Published: (2022-07-01)

Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure.
by: Paul McCusker, et al.
Published: (2021-03-01)

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting
by: Amara RO, et al.
Published: (2018-08-01)

Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration
by: Crellen, T, et al.
Published: (2016)

Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails
by: Flávia FB Couto, et al.
Published: (2011-03-01)

The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni
by: Maria João Gouveia, et al.
Published: (2019-06-01)

Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease.
by: Watt, G, et al.
Published: (1988)

Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
by: Noemi Cowan, et al.
Published: (2015-08-01)

Schistosoma mansoni: histological analysis of the synergistic interaction between vaccine immunity and praziquantel therapy in the lungs of mice.
by: Piper, K, et al.
Published: (1990)

Development of a field diagnostic tool for Schistosoma mansoni Praziquantel resistant markers in selected endemic communities
by: Maame Ekua Acquah, et al.
Published: (2024-03-01)

Complementary effect of Capparis spinosa L. and silymarin with/without praziquantel on mice experimentally infected with Schistosoma mansoni
by: El-Hawary S. S., et al.
Published: (2018-03-01)

Efficacy and Safety of Praziquantel for Treatment of <i>Schistosoma mansoni</i> Infection among School Children in Tanzania
by: Rajabu Hussein Mnkugwe, et al.
Published: (2019-12-01)

Praziquantel is an effective drug for the treatment of Schistosoma Mansoni infection among school-aged children in Northwest Ethiopia
by: Addisu Tesfie, et al.
Published: (2020-04-01)

The effects of subcurative praziquantel treatment on life‐history traits and trade‐offs in drug‐resistant Schistosoma mansoni
by: Mafalda Viana, et al.
Published: (2018-04-01)

Efficacy of Single-Dose Praziquantel for the Treatment of <i>Schistosoma mansoni</i> Infections among School Children in Rwanda
by: Joseph Kabatende, et al.
Published: (2023-09-01)

Effect of praziquantel administration on hepatic stereology of mice infected with Schistosoma mansoni and fed a low-protein diet
by: L.A. Barros, et al.
Published: (2009-09-01)

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection.
by: Melissa C Sanchez, et al.
Published: (2017-06-01)

Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial
by: Jean T Coulibaly, PhD, et al.
Published: (2017-07-01)

Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy
by: Amaya L. Bustinduy, et al.
Published: (2016-09-01)

Antiparasitic Activity of Mirazid, Myrrh Total Oil and Nitazoxanide Compared to Praziquantel on Schistosoma Mansoni: Scanning Electron Microscopic Study
by: Mona EL-SAYAD, et al.
Published: (2017-09-01)